AusBiotech

The year has seen the biotech sector unite to progress and deliver, as it is recognised as an invaluable industry that continues to exhibit its strength in innovation and leadership.

To compile an accurate and truly national picture of the capability and capacity of Australia’s health security ecosystem, including end-to-end supply chains and workforce, the Australian biotech industry is invited to contribute to the National Health Security Resilience Assessment, that is closing with the year.

CSL Limited (ASX:CSL) has announced the successful completion of its $6.3 billion institutional placement with proceeds to support the company's acquisition of Vifor Pharma.

Synthetic anti-infectives company Recce Pharmaceuticals (ASX:RCE) has announced it has recruited the first cohort of 10 healthy male subjects in its Phase I intravenous clinical trial of its lead compound.

A potential new treatment in development for multiple sclerosis created at QIMR Berghofer Medical Research Institute has secured a deal worth up to $63 million.

Cell therapy immuno-oncology company Carina Biotech has announced a new worldwide, exclusive license agreement with Bayerische Patentallianz for the CXCR6-transduced CAR-T cell technology.

Immunotherapy development company Immutep (ASX:IMM) has signed a Manufacturing Service Agreement with Northway Biotech.

Research Australia’s 18th Health and Medical Research Awards have been announced, and AusBiotech congratulates Professor Megan Munsie, Melbourne University, who was recognised for her ongoing advocacy work in stem cells.

Agtech development company Bio-Gene Technology (ASX: BGT) announced it has secured commitments to raise $3.2 million through a strategic share placement to sophisticated and professional investors.

Starpharma (ASX:SPL) has signed a commercial arrangement for its antiviral nasal spray Viraleze in Vietnam with orders in excess of 2 million since late October.

Chimeric Therapeutics (ASX:CHM) has announced several planned changes to key management roles for 2022.

Unlisted Australian company Servatus has announced it has secured $7.5 million in an oversubscribed capital raise.